Literature DB >> 29945026

Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.

Rui Tada1, Hidehiko Suzuki2, Saeko Takahashi3, Yoichi Negishi3, Hiroshi Kiyono4, Jun Kunisawa5, Yukihiko Aramaki3.   

Abstract

Infectious diseases are the second leading cause of death worldwide, suggesting that there is still a need for the development of new and improved strategies for combating pathogens effectively. Streptococcus pneumoniae is the most virulent bacteria causing pneumonia with high mortality, especially in children and the elderly. Because of the emergence of antibiotic resistance in S. pneumoniae, employing a serotype-independent mucosal vaccine would be the best approach to prevent and treat the diseases caused by S. pneumoniae. In this study, we have developed a pneumococcal nasal vaccine, consisting of pneumococcal surface protein A (PspA) and cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and cholesteryl 3β-N-(dimethylaminoethyl)-carbamate (DC-chol) (DOTAP/DC-chol liposome). The efficiency of this cationic liposome-based PspA nasal vaccine was examined in a murine model of S. pneumoniae infection. Intranasal vaccination with PspA and DOTAP/DC-chol liposomes conferred protective immunity against lethal inhalation of S. pneumoniae, improving the survival rate of infected mice. Moreover, intranasal immunization with PspA and DOTAP/DC-chol liposomes not only induced the production of PspA-specific IgA and IgG by both mucosal and systemic compartments but also elicited PspA-specific Th17 responses, which play a pivotal role in controlling S. pneumoniae infection by host innate immune response. We further demonstrated that DOTAP/DC-chol liposomes enhanced PspA uptake by nasal dendritic cells (DCs), which might be a mechanism for the induction of protective immune responses to S. pneumoniae infection. These results show that DOTAP/DC-chol liposome would be an efficient mucosal vaccine system for a serotype-independent universal nasal vaccine against pneumococcal infection.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cationic liposome; Mucosal vaccine; Nasal vaccine; PspA; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2018        PMID: 29945026     DOI: 10.1016/j.intimp.2018.06.027

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  13 in total

Review 1.  Understanding the Phagocytosis of Particles: the Key for Rational Design of Vaccines and Therapeutics.

Authors:  Silvia Moreno-Mendieta; Daniel Guillén; Nathaly Vasquez-Martínez; Rogelio Hernández-Pando; Sergio Sánchez; Romina Rodríguez-Sanoja
Journal:  Pharm Res       Date:  2022-06-23       Impact factor: 4.580

Review 2.  Cationic Nanoparticle-Based Cancer Vaccines.

Authors:  Jeroen Heuts; Wim Jiskoot; Ferry Ossendorp; Koen van der Maaden
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 3.  Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease.

Authors:  William Walkowski; Justin Bassett; Manmeet Bhalla; Blaine A Pfeifer; Elsa N Bou Ghanem
Journal:  Vaccines (Basel)       Date:  2021-06-02

4.  Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection.

Authors:  Sudeep Kumar; Raju Sunagar; Edmund J Gosselin
Journal:  Vaccines (Basel)       Date:  2020-04-23

5.  Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation against Streptococcus pneumoniae Infections in Mice.

Authors:  Rui Tada; Hidehiko Suzuki; Miki Ogasawara; Daisuke Yamanaka; Yoshiyuki Adachi; Jun Kunisawa; Yoichi Negishi
Journal:  Pharmaceutics       Date:  2021-04-20       Impact factor: 6.321

6.  Enzymatically polymerised polyphenols prepared from various precursors potentiate antigen-specific immune responses in both mucosal and systemic compartments in mice.

Authors:  Rui Tada; Miki Ogasawara; Daisuke Yamanaka; Yasuhiro Sakurai; Yoichi Negishi; Hiroshi Kiyono; Naohito Ohno; Jun Kunisawa; Yukihiko Aramaki
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

Review 7.  Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit.

Authors:  Bharti Mangla; Shamama Javed; Muhammad H Sultan; Waquar Ahsan; Geeta Aggarwal; Kanchan Kohli
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

8.  Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.

Authors:  Rui Tada; Akira Hidaka; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki
Journal:  BMC Res Notes       Date:  2018-07-13

9.  Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity.

Authors:  Rui Tada; Akihiro Ohshima; Yuya Tanazawa; Akari Ohmi; Saeko Takahashi; Hiroshi Kiyono; Jun Kunisawa; Yukihiko Aramaki; Yoichi Negishi
Journal:  Vaccines (Basel)       Date:  2019-12-27

10.  The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes.

Authors:  Seo Ri Wui; Ara Ko; Ji In Ryu; Eojin Sim; Soo Jeong Lim; Shin Ae Park; Kwang Sung Kim; Ha Kim; Hyewon Youn; Na Gyong Lee
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.